Analyst Price Targets — KYNB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 2, 2023 2:00 am | Annabel Samimy | Stifel Nicolaus | $28.00 | $17.32 | StreetInsider | Stifel Upgrades FibroGen (FGEN) to Buy |
Latest News for KYNB
Pharmaxis (OTCMKTS:PXSLY - Get Free Report) and Kyntra Bio (NASDAQ: KYNB - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Analyst Ratings This is a summary of recent
SAN FRANCISCO, June 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) treated with roxadustat will be presented as a poster at the European Hematology Association (EHA) Congress 2026, taking place June 11-14, 2026…
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Kyntra Bio (KYNB) came out with a quarterly loss of $3.74 per share versus the Zacks Consensus Estimate of a loss of $3.36. This compares to a loss of $4 per share a year ago.
SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provided an update on the company's recent developments.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KYNB.
U.S. House Trading
No House trades found for KYNB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.